Parkinson's disease
Conditions
Interventions
Parkinson's disease:NO
Parkinson's disease with chronic appendicitis-like lesions:NO
Parkinson's disease without chronic appendicitis-like lesions:NO
Sponsors
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Parkinson's disease/ dementia: 1. Meet the 2015 MDS and the 2007 MDS diagnostic criteria; 2. slow movement of the patient, combined stationary tremor, and/ or muscle rigidity; 3. A clear and significant effective response to the treatment of dopamine-capable drugs; the presence of levodopa-induced dyskinesia; 4. a single limb-stationary tremor (prior or this test) recorded in a clinical physical examination; 5. at least one additional test result positive for the differential diagnosis of PD-specific greater than 80%; 6. the informed consent of all subjects and their guardians to this study and the signing of the informed consent form; The criteria for inclusion of the dementia in Parkinson's disease: 1. Meet the PD diagnosis; 2. After 1 year, the cognitive impairment of slow progress has been hidden, and the daily living ability of the patient has been affected; 3. at least two of the cognitive function assessment (attention, execution, visual space ability and memory) are abnormal.
Exclusion criteria
Exclusion criteria: Parkinson's disease: 1. clear cerebellar abnormalities, such as cerebellar gait, limb ataxia, or cerebellar eye movement abnormalities; 2. downward supranuclear gaze paralysis, or selective downward vertical scan deceleration; 3. within 5 years of onset, it was diagnosed as likely behavioral variant frontotemporal lobe dementia or primary progressive aphasia; 4. the onset of Parkinson's syndrome was still limited to lower extremity Parkinson's syndrome for more than 3 years; 5. dopamine receptor blocker or dopamine depletion agent was used in the treatment of Parkinson's syndrome, and the dose and time process was consistent with that of drug-induced Parkinson's syndrome; 6. although the condition was at least moderate severity, there was no observable therapeutic response to high dose levodopa treatment; 7. clear cortical sensory loss, clear motor aphasia or progressive aphasia of limb concept; 8. normal neuroimaging examination of presynaptic dopamine system function; 9. clearly recorded Parkinson's syndrome or other diseases suspected to be related to the symptoms of the patient; 10. subjects who could not cooperate with the relevant examination.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| appendix MSSCT test;MDS-UPDS;PDQ-39;H-Y;NMSQ;SCOPA-AUT;MOCA;ESS;PSQI;RBDQ-HK;HAMA;HAMD;UPSIT;FSS;MRI of brain;18F-FDG-PET of brain; | — |
Countries
China
Contacts
Public ContactYuhua Chen
Outcome results
None listed